Evidence map›Paper›PMID 41822056›Full record

ReviewClinical kidney journal2026

Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.

Safak Mirioglu, Johann Morelle, Orhan Efe, Ozge Hurdogan, Ahmet Burak Dirim, Gizem Kumru, Krista L Lentine, Yasar Caliskan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Eculizumab for ATCR-associatedFrontiers in medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Safak MiriogluDivision of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-0362-8154
Johann MorelleDivision of Nephrology, University Hospitals Namur (CHU UCL Namur), Namur, Belgium.ORCID https://orcid.org/0000-0002-6925-1989
Orhan EfeDivision of Nephrology, Massachusetts General Hospital, Mass General Brigham, Boston, MA, USA.ORCID https://orcid.org/0000-0003-4852-9061
Ozge HurdoganDepartment of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Ahmet Burak DirimDivision of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Gizem KumruDivision of Nephrology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Turkey.ORCID https://orcid.org/0000-0001-7529-3010
Krista L LentineSSM Health Saint Louis University Hospital Transplant Center, Saint Louis University, St. Louis, MO, USA.ORCID https://orcid.org/0000-0002-9423-4849
Yasar CaliskanSSM Health Saint Louis University Hospital Transplant Center, Saint Louis University, St. Louis, MO, USA.ORCID https://orcid.org/0000-0003-3816-8047

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects ∼0.8%-14% of kidney transplant recipients, and may manifest as either a recurrent or

Indexed as

alternative complement pathwayatypical hemolytic uremic syndromeeculizumabkidney transplantationthrombotic microangiopathy

Identifiers

PMID41822056
PMCPMC12976228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.